Hereditary Angioedema Therapeutic Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

The hereditary angioedema therapeutic market was valued at USD 3.41 Billion in 2025. It is poised to grow at a CAGR of 7.80% during the forecast period of 2026-2035, and reach USD 7.23 Billion by 2035. Growth is fueled by rising adoption of long-term prophylaxis and a wave of new oral and RNA-targeted approvals.

Latest News on the Hereditary Angioedema Therapeutic Market (2026)

April 2026: KalVista Presents Sebetralstat Updates at Needham Healthcare Investor Conference

According to BioPharma Dive, KalVista Pharmaceuticals presented updates on EKTERLY (sebetralstat) at the Needham Virtual Healthcare Conference on April 15. Following seven global regulatory approvals in 2025, the first oral on-demand therapy for hereditary angioedema continues expanding commercial reach, reinforcing the shift toward oral, self-administered treatment options and intensifying competition among prophylactic and acute therapy providers worldwide.

March 2026: KalVista Reports Positive Pediatric Angioedema Phase Three Trial Data

As reported by Contemporary Pediatrics, KalVista announced positive interim KONFIDENT-KID results on March 30 at the Global Angioedema Leadership Conference in Madrid. Children aged two to eleven demonstrated rapid symptom relief with oral sebetralstat. A US pediatric filing is planned for the third quarter of 2026, potentially broadening market access to underserved populations currently reliant on injectable therapies.

Key Market Trends and Insights

• By drug class, the kallikrein inhibitor segment held approximately 46% market share in the historical period.
• Based on the treatment type, the acute/on-demand treatment accounted for nearly 60% market in the historical period.
• By route of administration, the intravenous route held the largest market share of around 54% in the historical period.

Market Size and Forecast

• Market Size (2025): USD 3.41 Billion
• Projected Market Size (2035): USD 7.23 Billion
• CAGR (2026-2035): 7.80%
• Largest Market in 2025: North America

Hereditary Angioedema Therapeutic Market Overview

Hereditary angioedema is a rare autosomal dominant disorder caused by deficient or dysfunctional C1 esterase inhibitor protein, leading to recurrent swelling attacks of the skin, abdomen, face, and larynx. The market was valued at USD 3.41 Billion in 2025 and is expanding steadily with the rising adoption of prophylactic treatments, growing research investments, favorable regulatory support, and the development of innovative plasma-derived and monoclonal antibody therapies. Increasing healthcare access and strategic collaborations among biopharmaceutical companies are further supporting market growth.

Hereditary Angioedema Therapeutic Market Growth Drivers

Rising Disease Prevalence is Likely to Accelerate the Market Expansion

Increasing awareness of hereditary angioedema and advancements in diagnostic capabilities are significantly driving the growth of the market. Greater recognition of recurrent swelling symptoms among healthcare professionals has improved early diagnosis and treatment adoption. According to Healio, hereditary angioedema affects approximately one person per 50,000 individuals globally, while a 2024 systematic review estimated a prevalence ranging from 0.13 to 1.60 cases per 100,000 people. The growing identification of diagnosed patient populations is supporting higher demand for targeted therapies and encouraging continued therapeutic innovation and market expansion.

Hereditary Angioedema Therapeutic Market Trends

The market is witnessing several trends, including targeted biologics and convenient prophylactic treatment advancements.

Targeted Factor XIIa Inhibition is Likely to Boost the Market Growth

The growing focus on targeted prophylactic therapies with convenient dosing regimens is emerging as a significant trend in the market. For instance, in June 2025, CSL announced the U.S. Food and Drug Administration approval of ANDEMBRY® (garadacimab-gxii), a once-monthly prophylactic hereditary angioedema treatment targeting factor XIIa. The therapy demonstrated a substantial reduction in hereditary angioedema attacks and enhanced long-term disease control. Such advancements are expected to improve treatment adherence, expand therapeutic options, and accelerate the overall market growth.

Hereditary Angioedema Therapeutic Market Segmentation

Market Breakup by Drug Class

• C1-Esterase Inhibitor
• Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Others

Market Breakup by Treatment Type

• Acute / On-Demand Treatment
• Long-term Prophylaxis

Market Breakup by Patient Type

• Type I (C1-INH Deficiency)
• Type II (C1-INH Dysfunction)
• nC1-INH (Type III and Others)

Market Breakup by Route of Administration

• Oral
• Intravenous
• Subcutaneous Injection

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Others

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Hereditary Angioedema Therapeutic Market Share

C1 Esterase Inhibitors Segment Likely to Lead the Market by Drug Class

The market is segmented by drug class into C1 esterase inhibitors, selective bradykinin B2 receptor antagonists, kallikrein inhibitors, and others. Among these, C1 esterase inhibitors are expected to lead the market owing to their proven effectiveness in preventing and treating hereditary angioedema attacks, along with their widespread clinical acceptance and availability of advanced formulations. The growing preference for targeted therapies, rising diagnosis rates, and increasing awareness regarding long-term disease management are further supporting segment expansion. In addition, favorable treatment outcomes and continued focus on improving patient quality of life are expected to strengthen the dominance of this segment over the forecast period.

Hereditary Angioedema Therapeutic Market Analysis by Region

Among all the regions, the United States is expected to witness significant growth in the market due to advanced healthcare infrastructure, strong regulatory support, and increasing adoption of innovative therapies for rare diseases. For instance, in August 2025, the U.S. Food and Drug Administration approved Dawnzera by Ionis Pharmaceuticals as the first RNA-targeted prophylactic therapy for hereditary angioedema. According to the company’s Phase III OASIS-HAE trial data, the therapy reduced monthly attack rates by 81%, supporting continued market growth through therapeutic innovation and improved patient outcomes.

Leading Players in the Hereditary Angioedema Therapeutic Market

The key features of the report include patent analysis, grants analysis, funding and investment analysis, and strategic initiatives. The major companies in the market are as follows:

BioCryst Pharmaceuticals, Inc.

BioCryst, headquartered in Durham, North Carolina, commercializes Orladeyo (berotralstat), the first once-daily oral plasma kallikrein inhibitor for HAE prophylaxis. In December 2025, the FDA approved an oral pellet formulation extending Orladeyo to children aged 2 to under 12 years.

Ionis Pharmaceuticals, Inc.

Ionis, Pharmaceuticals, Inc. is a biotechnology company focused on developing RNA-targeted therapies for rare diseases. The company strengthened its presence in the hereditary angioedema therapeutic market through the U.S. FDA approval of DAWNZERA, the first RNA-targeted prophylactic treatment for hereditary angioedema. The therapy demonstrated significant and sustained reduction in attack rates, supporting Ionis’ growing role in advancing long-term disease management solutions for hereditary angioedema patients.

Takeda Pharmaceutical Company Limited

Takeda, Takeda Pharmaceutical Company is a leading biopharmaceutical company headquartered in Japan. The company focuses on developing innovative therapies in rare diseases, gastroenterology, oncology, neuroscience, and plasma-derived treatments. In the hereditary angioedema therapeutic market, Takeda plays a significant role through Takhzyro, supporting long-term disease management and expanding patient access globally through continuous research and commercialization efforts.

Pharming Group N.V.

Pharming, headquartered in Leiden, Netherlands, markets Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor approved for on-demand treatment of acute HAE attacks in adults and adolescents. Ruconest is delivered intravenously and is approved across the United States, European Union, and many other markets.

Other key players include Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, Inc., Pharvaris N.V., Arrowhead Pharmaceuticals, Inc., and CSL Limited.

Key Questions Answered in the Hereditary Angioedema Therapeutic Market Report

• What was the hereditary angioedema therapeutic market value in 2025?
• What is the market forecast outlook for 2026-2035?
• What major factors aid demand for the hereditary angioedema therapeutic market?
• How has the market performed and how is it expected to perform ahead?
• What are the major drivers, opportunities, and restraints?
• What are the major hereditary angioedema therapeutic market trends?
• Which drug class is expected to dominate the market segment?
• Which treatment type is projected to lead the market segment?
• Which patient type is expected to lead the market?
• Which route of administration is anticipated to drive the market segment?
• Which distribution channel is expected to dominate the market segment?
• Who are the key players in the hereditary angioedema therapeutic market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, mergers, and acquisitions shaping market dynamics?